new
coronaviru
sarscov
within
famili
coronavirida
similar
cov
sarscov
envelop
viru
contain
larg
positivestrand
rna
genom
encod
viral
replicas
protein
four
major
structur
protein
includ
spike
membran
envelop
e
nucleocapsid
n
protein
uncharacter
compon
induc
immun
respons
viral
infect
therefor
postgenom
character
sarscov
highli
import
understand
pathogenesi
develop
diagnost
therapeut
vaccin
protein
sarscov
type
transmembran
glycoprotein
contain
put
subunit
fragment
locat
middl
region
subunit
residu
character
minim
receptorbind
domain
rbd
suffici
associ
angiotensinconvert
enzym
function
receptor
target
cell
subunit
contain
put
fusion
peptid
two
heptad
repeat
region
respons
fusion
viral
target
cell
membran
therefor
sarscov
infect
initi
attach
protein
via
rbd
specif
receptor
target
cell
form
fusogen
core
region
domain
bring
viral
target
cell
membran
close
proxim
result
viru
fusion
entri
second
major
properti
sarscov
protein
induc
neutral
antibodi
protect
immun
therebi
candid
develop
effect
vaccin
dna
vaccin
encod
protein
induc
sarscov
neutral
protect
immun
mice
vaccin
anim
recombin
virus
attenu
vaccinia
viru
mva
parainfluenza
viru
express
protein
elicit
neutral
antibodi
protect
anim
sarscov
challeng
infect
pseudoviru
express
sarscov
protein
effect
neutral
convalesc
sera
sar
patient
data
suggest
protein
sarscov
protect
antigen
although
antigen
properti
well
defin
recent
demonstr
rbd
sarscov
protein
major
target
neutral
antibodi
viral
infect
immun
suggest
potenti
applic
major
target
sar
vaccin
immunotherapeut
protein
sarscov
induc
antibodi
respons
infect
patient
mice
rabbit
immun
inactiv
sarscov
defin
immunoepitop
set
peptid
span
entir
sequenc
protein
sarscov
strain
peptid
contain
amino
acid
residu
residu
overlap
adjac
peptid
synthes
use
pepscan
analys
convalesc
sera
sar
patient
reveal
protein
contain
five
linear
immunodomin
site
correspond
sequenc
residu
design
site
v
immunodomin
site
iiii
v
react
convalesc
sera
sar
patient
site
iv
reactiv
sar
sera
overlap
peptid
also
use
probe
local
immunodomin
epitop
protein
sarscovimmun
mice
rabbit
interestingli
three
react
significantli
mous
antisera
resid
within
immunodomin
site
iv
similarli
peptid
correspond
ntermin
sequenc
site
iv
react
rabbit
antisera
therefor
major
linear
immunodomin
domain
site
iv
induc
antibodi
respons
human
also
mice
rabbit
investig
whether
immunodomin
epitop
induc
neutral
antibodi
design
synthes
longer
peptid
overlap
immunodomin
site
base
find
peptid
deriv
immunodomin
site
iii
respect
peptid
overlap
sequenc
major
immunodomin
site
iv
longer
peptid
without
conjug
carrier
abl
elicit
high
titer
antibodi
howev
none
rabbit
antisera
neutral
activ
sarscov
sar
pesudoviru
suggest
linear
immunodomin
site
neutral
epitop
found
convalesc
sera
sar
patient
contain
high
titer
rbdspecif
antibodi
identifi
neutral
epitop
sarscov
protein
fusion
protein
contain
rbd
residu
link
human
fc
fragment
design
rbdfc
use
isol
rbdspecif
antibodi
immunoaffin
chromatographi
patient
antisera
effici
deplet
recoveri
rbdspecif
antibodi
monitor
measur
reactiv
start
sera
correspond
flowthrough
elut
antibodi
fraction
elisa
rbd
subunit
neutral
activ
sampl
start
sera
flowthrough
eluat
determin
use
sar
pseudoviru
system
strikingli
neutral
neutral
antibodi
activ
immun
sera
dramat
reduc
deplet
antirbd
antibodi
antirbd
antibodi
eluat
possess
higher
potenc
antibodi
flowthrough
neutral
sar
pseudoviru
suggest
neutral
activ
antisera
contribut
rbdspecif
antibodi
observ
rbd
protein
major
target
neutral
antibodi
mice
rabbit
immun
inactiv
sarscov
vaccin
mice
rabbit
develop
high
titer
antibodi
protein
rbd
three
immun
mean
endpoint
titer
mous
rabbit
antisera
rbd
respect
mous
rabbit
antisera
could
effici
block
bind
rbdfc
use
pseudoviru
bear
sarscov
protein
demonstr
mous
rabbit
antisera
significantli
inhibit
proteinmedi
viru
entri
mean
inhibitori
titer
respect
elucid
neutral
determin
sarscov
rbdspecif
antibodi
isol
immunoaffin
chromatographi
rabbit
antisera
similarli
reactiv
antirbd
antibodi
rabbit
antisera
could
effici
deplet
rbdfc
affin
column
flowthrough
bind
rbdfc
elut
antirbd
antibodi
significantli
react
rbdfc
neutral
activ
antirbd
antibodydeplet
rabbit
antisera
much
lower
start
sera
antirbd
antibodi
possess
potent
activ
neutral
sar
pseudoviru
data
suggest
rbd
protein
effect
induc
neutral
antibodi
immun
anim
evalu
whether
rbd
serv
effect
vaccin
rbdfc
protein
use
immunogen
immun
mice
rabbit
anim
mice
rabbit
develop
robust
antibodi
respons
rbdfc
boost
antisera
contain
high
titer
antibodi
specif
rbd
shown
elisa
use
subunit
antigen
mean
endpoint
titer
mous
rabbit
antisera
protein
respect
antisera
test
neutral
activ
use
two
differ
assay
system
ie
infect
sarscov
vero
sar
pseudoviru
cell
express
strikingli
mous
rabbit
antisera
abl
effect
neutral
live
sarscov
infect
mean
neutral
titer
infect
cell
sar
pseudoviru
could
potent
inhibit
character
neutral
determin
rbd
protein
isol
panel
monoclon
antibodi
mab
rbdfcimmun
mice
six
group
conformationdepend
epitop
design
conf
ivi
two
adjac
linear
epitop
identifi
elisa
bind
competit
assay
conf
iv
v
mab
could
effici
block
rbd
bind
mab
react
conf
iii
vi
partial
inhibit
interact
rbd
suggest
epitop
may
overlap
receptorbind
site
rbd
bind
mab
rbd
may
caus
conform
chang
receptor
bind
site
result
inhibit
rbd
bind
mab
also
highli
potent
neutral
activ
sarscov
sar
pseudoviru
infect
mab
recogn
conf
ii
could
significantli
affect
rbd
bind
also
effici
neutral
sarscov
suggest
may
use
uniqu
mechan
block
infect
data
indic
rbd
induc
neutral
antibodi
specif
receptorbind
site
also
structur
conform
notabl
two
mab
target
linear
sequenc
virusneutr
abil
therefor
rbd
sar
protein
contain
multipl
conform
epitop
capabl
induc
potent
neutral
antibodi
respons
summari
propos
use
rbd
sarscov
develop
vaccin
immunotherapeut
function
domain
mediat
virusreceptor
bind
also
major
target
neutral
antibodi
viru
infect
vaccin
independ
fold
rbd
contain
multipl
neutral
epitop
induc
effect
protect
antibodi
